SONM vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

SONM

25.0
AI Score
VS
HIVE Wins

HIVE

40.3
AI Score

Investment Advisor Scores

SONM

25score
Recommendation
AVOID NEW MONEY

HIVE

40score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric SONM HIVE Winner
Forward P/E 3.1676 62.8931 SONM
PEG Ratio 0.2527 0 Tie
Revenue Growth 7.9% 73.5% HIVE
Earnings Growth 255.0% -99.9% SONM
Tradestie Score 25.0/100 40.3/100 HIVE
Profit Margin 0.0% -98.5% SONM
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD HIVE

Relative Price Performance (Last 90 Days)

SONM 1M: +24.3% · 3M: -3.1% HIVE 1M: +9.4% · 3M: -12.0%

Current Technical Phase

SONM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 55.6 · Price: $4.08

HIVE

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -2.6%) with fading momentum, RSI 46

RSI (14): 46.5 · Price: $2.98

Fundamentals Snapshot

Metric SONM HIVE
Market Cap — —
Forward P/E 3.2 -5.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.1% 0.7%
Gross Margin 0.1% 0.4%
Operating Margin 0.5% -0.6%
EPS -7.57 -1.39
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.